Aprocitentan in resistant hypertension

Aprocitentan in resistant hypertension Since the 1960s, modern studies of hypertension and the availability of antihypertensive drugs have significantly improved blood pressure control. However, it has reached a plateau in high-income countries in the past decade. Many patients who have uncontrolled BP despite three antihypertensive treatments at optimal dose and from

Hypertension Screening for Cardiovascular Health

Hypertension Screening for Cardiovascular Health Introduction Hypertension is a contributing risk factor for cardiovascular health. In the recent European Society of Cardiology (ESC) guidelines, the main recommendation for antihypertensive treatment of patients was regarded by the future risk of cardiovascular (CV) mortality, CV disease, or total mortality. The guideline state that the

Blood pressure and CVD risk reduction

Blood pressure and CVD risk reduction Cardiovascular disease (CVD) is the primary cause of death worldwide, and in underdeveloped countries such as Haiti. It’s also found that among cardiovascular problems, hypertension is the leading risk factor. In this study, the researcher’s goal was to identify gaps in the hypertension continuum of

Community Hypertension and Atherosclerosis Risk

Community Hypertension and Atherosclerosis Risk Elevated blood pressure (BP) is considered one of the key risk factors in deaths caused by cardiovascular and renal problems. Despite the increase in awareness about hypertension and the advancements in treatment through the last decades, many patients still suffer from elevated BP while on treatment.

Aprocitentan in resistant hypertension